{{Rsnum
|rsid=2228014
|Gene=CXCR4
|Chromosome=2
|position=136115514
|Orientation=minus
|GMAF=0.05969
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CXCR4
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 0.0 | 0.0
| HCB | 75.6 | 22.2 | 2.2
| JPT | 86.4 | 13.6 | 0.0
| YRI | 95.2 | 4.8 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 75.6 | 22.2 | 2.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID|21292343}}  the TT genotype increased 6.5X risk of [[lung cancer]] compared with CC genotype in chinese.

{{PMID Auto
|PMID=18781190
|Title=Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study).
|OA=1
}}

{{PMID Auto
|PMID=19196101
|Title=Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan.
}}

{{PMID Auto
|PMID=19327121
|Title=Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma.
}}

{{PMID Auto
|PMID=19812382
|Title=Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia.
}}

{{PMID Auto
|PMID=21304904
|Title=Genetic predisposition of donors affects the allograft outcome in kidney transplantation; polymorphisms of stromal-derived factor-1 and CXC receptor 4.
|OA=1
}}

{{PMID Auto
|PMID=23711392
|Title=The CXCL12-3'A allele plays a favourable role in patients with multiple myeloma
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}